Annals of Indian Academy of Neurology
  Users Online: 2429 Home | About the Journal | InstructionsCurrent Issue | Back IssuesLogin      Print this page Email this page  Small font size Default font size Increase font size

Table of Contents
LETTER TO THE EDITOR
Year : 2014  |  Volume : 17  |  Issue : 4  |  Page : 480-481
 

Efficacy and safety of methylcobalamin, alpha lipoic acid and pregabalin combination versus pregabalin monotherapy in improving pain and nerve conduction velocity in type 2 diabetes associated impaired peripheral neuropathic condition. [MAINTAIN]: Results of a pilot study


1 The Brain Spine and Nerve Centre, Chennai, Tamil Nadu, India
2 Medical Services, Abbott Healthcare Pvt. Limited, Mumbai, Maharashtra, India

Date of Web Publication5-Nov-2014

Correspondence Address:
Manoj M Naik
Abbott Healthcare Pvt. Limited, 'D' Mart Building, Opposite Wockhardt Hospital, Goregaon Mulund Link Road, Mulund (W), Mumbai - 400 080, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0972-2327.144048

Rights and Permissions

 



How to cite this article:
Vasudevan D, Naik MM, Mukaddam QI. Efficacy and safety of methylcobalamin, alpha lipoic acid and pregabalin combination versus pregabalin monotherapy in improving pain and nerve conduction velocity in type 2 diabetes associated impaired peripheral neuropathic condition. [MAINTAIN]: Results of a pilot study. Ann Indian Acad Neurol 2014;17:480-1

How to cite this URL:
Vasudevan D, Naik MM, Mukaddam QI. Efficacy and safety of methylcobalamin, alpha lipoic acid and pregabalin combination versus pregabalin monotherapy in improving pain and nerve conduction velocity in type 2 diabetes associated impaired peripheral neuropathic condition. [MAINTAIN]: Results of a pilot study. Ann Indian Acad Neurol [serial online] 2014 [cited 2019 Dec 5];17:480-1. Available from: http://www.annalsofian.org/text.asp?2014/17/4/480/144048


Sir,

This is in response to the comments on published article entitled, "Efficacy and safety of methylcobalamin, alpha lipoic acid and pregabalin combination versus pregabalin monotherapy in improving pain and nerve conduction velocity in type 2 diabetes associated impaired peripheral neuropathic condition. [MAINTAIN]: Results of a pilot study" published in Annals of Indian Academy of Neurology (Ann Indian Acad Neurol 2014;17:19-24). [1]

We really appreciate detailed review, analysis, and comments on the study procedure by the author in a letter to editor. We wish to clarify the details on issues raised:

No treatment or placebo-control treatments are two different subtypes of concurrently control group. Control groups used in the clinical trials can be classified into two main types: Concurrent control or historical control. [2]

Concurrent control: In this type, the control group and test groups are selected from the same population and treatment is given concurrently. Four different subtypes of control groups can be used in concurrently controlled types: placebo control, no treatment, different dose or regimen of the study treatment, or a different active treatment.

External (historical) control: In this type, the control group is the group of patients treated earlier (historical) control or patients treated during the same time period but in another setting.

In our study, the control arm was from the first category i.e., concurrently controlled (different active treatment).

We agree about the practical difficulty of conducting randomization, precautions to be taken in randomization procedure and allocation concealment to avoid bias. Both of these procedures were followed in our "Pilot" study. A total of 30 patients were randomly assigned (1:1) to two treatment groups. The patients were treated based on a pre-determined computer-generated randomization code which were prepared by a person other than investigator and were provided to the investigator in a sealed envelope separately for each patient to ensure allocation concealment. The approach of dividing alternating subjects between one group and the other was not used in the study.

 
   References Top

1.
Vasudevan D, Naik MM, Mukaddam OI. Efficacy and safety of methylcobalamin, alpha lipoic acid and pregabalin combination versus pregabalin monotherapy in improving pain and nerve conduction velocity in type 2 diabetes associated impaired peripheral neuropathic condition. [MAINTAIN]: Results of a pilot study. Ann Indian Acad Neurol 2014;17:19-24.  Back to cited text no. 1
[PUBMED]  Medknow Journal  
2.
E 10 Choice of control group and related issues in clinical trials. Guidance for industry. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). May 2001. ICH. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073139.pdf [Last accessed on 2014 May 7].  Back to cited text no. 2
    




 

Top
Print this article  Email this article

    

 
   Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (390 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    References

 Article Access Statistics
    Viewed1226    
    Printed18    
    Emailed0    
    PDF Downloaded60    
    Comments [Add]    

Recommend this journal